Merck & Co (MRK)
$84.12 0.84 (1.01%)
19:17 EST MRK Stock Quote Delayed 15 Minutes
Previous Close $84.12
Market Cap 226.31B
PE Ratio 145.03
Volume (Avg. Vol.) 8.22M
Day's Range 83.58 - 84.82
52-Week Range 70.89 - 87.35
Dividend & Yield 1.92 (2.28%)
MRK Stock Predictions, Articles, and Merck & Co News
- From InvestorPlace
- From the Web
Thursday's 3 big stock charts highlight 3 recent movers that could rally if broad market optimism continues.
Some of today's malaise can be attributed to Alphabet (NASDAQ:GOOGL,GOOG), which declined following a disappointing earnings report issued yesterday after the market closed. The internet search giant reported earnings of $10.12 a share on revenue of $40.50 billion while analysts expected earnings of $12.42 on revenue of $40.32 billion.
The S&P 500 hit another new all-time high on Tuesday. Here's what happened in the stock market today to get it there.
In this volatile market, blue-chip stocks will get you through. Here are five of the bluest stocks to buy today.
A divided Federal Reserve is a new issue for investors to consider. Read more about what happened in the Dow Jones today.
The stock charts of MSFT, FB and MRK have earned a closer technical look as the new trading week kicks off.
Bristol-Myers Squibb stock touched a multi-year low last month. But the BMY stock price is cheap enough now to take on real risks.
Here we looked for five of the Street’s highest-rated Dow Jones stocks right now. As you will see all five of these stocks show a firm ‘Strong Buy’ Street consensus. That's based on all the ratings received by each stock over the last three months.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Longstanding cycles in CVS Health and Merck are at risk of changing and offering profits to spread traders buying CVS stock and shorting MRK.
Options trading was buzzing in Bed Bath & Beyond, CVS, and Merck on Thursday. Here are the metrics that matter moving forward.
The stock charts of HollyFrontier, Activision Blizzard and Vertex Pharmaceuticals are poised to end the trading week in a pivotal situation.
As has been noted in this space, market participants are pricing in the following Fed facts: no interest rate cut this month and no cuts totaling 50 basis points this year. Hope burns eternal for a rate reduction of 25 basis points, but Powell's two-day testimony and the June meeting minutes could indicate otherwise.
MRK stock and ABBV stock are promising healthcare stocks to invest in from the XLV fund. MRK is 6% of holdings and AbbVie makes up 3.5%.
Play a friendly and widening price spread in biotech stocks with a well-place purchase in Merck and an equally smart short in AbbVie.
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!